SIROGEN
Dead / Abandoned — Abandoned — no statement of use filed (as of 16 Oct 2025)
What this means for you
This application is over — abandoned 16 Oct 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 97338000
- Mark type
- Stylized text
- Filed
- 30 Mar 2022
- Published for opposition
- 04 Apr 2023
- Abandoned
- 16 Oct 2025
- Attorney of record
- Michael Bamberger, Esq.
Goods and services
- Class 005 — Pharmaceuticals: A combination drug product, namely, a pharmaceutical ingredient in the nature of a formulation of sirolimus incorporated within a collagen membrane, which, an implantable drug carrier, enables local delivery of sirolimus to the vascular wall, administered by physicians during surgery
Owner
- Vascular Therapies, Inc., Cresskill, NJ, US
- Vascular Therapies, Inc., Cresskill, NJ, US
Prosecution history
- 16 Oct 2025 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 16 Oct 2025 — ABANDONMENT - NO USE STATEMENT FILED
- 24 Oct 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 24 Oct 2024 — SOU EXTENSION 3 GRANTED
- 24 Oct 2024 — SOU EXTENSION 3 FILED
- 24 Oct 2024 — SOU TEAS EXTENSION RECEIVED
- 30 May 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 29 May 2024 — SOU EXTENSION 2 GRANTED
- 29 May 2024 — SOU EXTENSION 2 FILED
- 29 May 2024 — SOU TEAS EXTENSION RECEIVED
- 24 Nov 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 22 Nov 2023 — SOU EXTENSION 1 GRANTED
- 22 Nov 2023 — SOU EXTENSION 1 FILED
- 22 Nov 2023 — SOU TEAS EXTENSION RECEIVED
- 30 May 2023 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT